These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16258527)

  • 1. PDE5 inhibition and fibrosis.
    Corbin J
    Int J Impot Res; 2005; 17(6):546. PubMed ID: 16258527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase type 5 inhibithors in older males.
    Frajese GV; Pozzi F
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 5. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
    Nagendran J; Archer SL; Soliman D; Gurtu V; Moudgil R; Haromy A; St Aubin C; Webster L; Rebeyka IM; Ross DB; Light PE; Dyck JR; Michelakis ED
    Circulation; 2007 Jul; 116(3):238-48. PubMed ID: 17606845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats.
    Ahn GJ; Sohn YS; Kang KK; Ahn BO; Kwon JW; Kang SK; Lee BC; Hwang WS
    Int J Impot Res; 2005; 17(2):134-41. PubMed ID: 15578039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
    Greco EA; Spera G; Aversa A
    Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
    Lincoln TM
    Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
    [No Abstract]   [Full Text] [Related]  

  • 9. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
    Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men.
    Matic H; McCabe MP
    Int J Impot Res; 2007; 19(4):418-23. PubMed ID: 17538638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
    Mehrotra N; Gupta M; Kovar A; Meibohm B
    Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor.
    Jung HG; Shin JH; Kim KW; Yu JY; Kang KK; Ahn BO; Kwon JW; Yoo M
    Life Sci; 2007 Jan; 80(7):699-708. PubMed ID: 17137605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?
    Oliver JJ
    Int J Clin Pract; 2006 Sep; 60(9):1026-7. PubMed ID: 16939541
    [No Abstract]   [Full Text] [Related]  

  • 15. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
    Burnett AL
    Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
    [No Abstract]   [Full Text] [Related]  

  • 16. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Hotston M; Shukla N; Bloor J; Persad R; Jeremy JY
    BJU Int; 2006 Dec; 98(6):1331-2. PubMed ID: 17125493
    [No Abstract]   [Full Text] [Related]  

  • 17. Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
    Jiang W; Sui Z; Macielag MJ; Walsh SP; Fiordeliso JJ; Lanter JC; Guan J; Qiu Y; Kraft P; Bhattacharjee S; Craig E; Haynes-Johnson D; John TM; Clancy J
    J Med Chem; 2003 Jan; 46(3):441-4. PubMed ID: 12540243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
    Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
    J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms.
    Grimsley SJ; Khan MH; Jones GE
    Med Hypotheses; 2007; 69(1):25-6. PubMed ID: 17300876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.